Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05958667 · ClinicalTrials.gov registry record · NA
Quitxt Mobile Text Messaging Cessation Research Study
A NA study, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- NA
- Development phase
- 1,200
- Enrollment target
NCT05958667: Recruiting NA study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT05958667 is a NA study that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 1,200 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05958667, a NA study, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
The health benefits of smoking cessation by age 30 are much greater than cessation later in life, including gaining 10 years of life, compared with those who continue to smoke. The goal of the proposed study is to evaluate the effectiveness of the bilingual and culturally tailored Quitxt mobile cessation intervention. Quitxt provides interactive messages through texts or chat with visual and video content employing theory- and evidence-based techniques to prompt and sustain cessation. The study will recruit 1,200 Latino young adult smokers aged 18-29 who enroll and agree to make quit attempts, with half randomly assigned (like flipping a coin) to receive Quitxt and half to abbreviated text messages with smoking cessation-related content and referral to the Texas Department of State Health Services cessation program Yes Quit (which has diverse formats, but not explicitly tailored for young Latino adults in South Texas). Participants respond to baseline and follow-up assessments at one, three and six months after their enrollment, and those who report cessation will be asked to provide saliva samples to confirm they quit smoking. The sample size will be sufficient to detect expected higher cessation rates in those who are enrolled in Quitxt than those who are enrolled in Texas DSHS Yes Quit. The investigators will publish results in scientific journals, report them at scientific and community meetings, share them on social media, and publicize them widely. This study has the potential to advance public health by evaluating the effectiveness of a scalable, easily disseminated and adaptable intervention to help young adults, especially Latinos, quit smoking and reduce smoking-related cancer and chronic disease morbidity and mortality and their associated healthcare costs.
Primary Outcome
Measure of smoking cessation (7-day point prevalence abstinence)self-reported and biochemically verified.
Interventions
- OTHER Usual care
- BEHAVIORAL Quitxt text messaging or Chat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2026-02-12 |
| Est. Completion | 2028-08 |
| Phase | NA |
What NCT05958667 shows while recruiting
NCT05958667 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 2 interventions - of which Usual care is the first listed.
NCT05958667 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05958667 about?
NCT05958667 is a clinical study titled "Quitxt Mobile Text Messaging Cessation Research Study". The health benefits of smoking cessation by age 30 are much greater than cessation later in life, including gaining 10 years of life, compared with those who continue to smoke. The goal of the proposed study is to evaluate the effectiveness of the bilingual and culturally tailored Quitxt mobile cess...
What is the current status of trial NCT05958667?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,200 participants. The study started on 2026-02-12. Estimated completion is 2028-08.
What interventions are being tested in trial NCT05958667?
The interventions under investigation include: Usual care (OTHER), Quitxt text messaging or Chat (BEHAVIORAL).
Who is sponsoring clinical trial NCT05958667?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05958667's enrollment target sits among peer trials
1,200 83rd of 2000 higher than 1,912 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI